BiotechTube

Istradefylline (KW-6002)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Nov 1, 2004 → Nov 1, 2005

NCT ID
NCT00199394

About Istradefylline (KW-6002)

Istradefylline (KW-6002) is a phase 3 stage product being developed by Kyowa Kirin for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00199394. Target conditions include Parkinson's Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (8)

NCT IDPhaseStatus
NCT00250393Phase 2Completed
NCT00199446Phase 2Completed
NCT00199433Phase 2Completed
NCT00199355Phase 2Completed
NCT00199394Phase 3Completed
NCT00199420Phase 3Completed
NCT00199407Phase 3Completed
NCT00456794Phase 2Completed

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
PerampanelEisaiPhase 2
52

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85